Affordable Access

Publisher Website

Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword

Elsevier Inc.
DOI: 10.1053/j.jrn.2013.01.022
  • Biology
  • Medicine


End-stage renal disease (ESRD) is associated with a significant propensity for development of atherosclerosis and cardiovascular mortality. The atherogenic diathesis associated with ESRD is driven by inflammation, oxidative stress, and dyslipidemia. Reduced high-density lipoprotein cholesterol (HDL-C) level and high-density lipoprotein (HDL) dysfunction are the hallmarks of ESRD-related dyslipidemia. Clinical and laboratory studies have revealed that ESRD is associated with significantly reduced serum apolipoprotein A-I (ApoA-I) and HDL-C level as well as altered HDL composition. Furthermore, although ESRD is associated with impaired HDL antioxidant and anti-inflammatory properties in most patients, in a small subset, HDL may in fact have a pro-oxidant and proinflammatory effect. Therefore, it is no surprise that serum HDL-C level is not a dependable indicator of cardiovascular disease burden in ESRD, and markers such as HDL function are critical to accurately identifying patients at risk for cardiovascular disease and mortality in ESRD.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Endothelin system: the double-edged sword in healt...

on Annual review of pharmacology... 2001

A double-edged sword.

on Journal of hospital medicine January 2013

Double-edged sword?

on JAMA internal medicine Jul 08, 2013

A double-edged sword.

on Nature reviews. Drug discovery April 2008
More articles like this..